APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability by Sansregret, L et al.
APC/C Dysfunction Limits Excessive Cancer Chromosomal 
Instability
Laurent Sansregret1, James O. Patterson#1, Sally Dewhurst#1, Carlos López-García1, André 
Koch2, Nicholas McGranahan1,3, William Chong Hang Chao1, David J. Barry1, Andrew 
Rowan1, Rachael Instrell1, Stuart Horswell1, Michael Way1, Michael Howell1, Martin R. 
Singleton1, René H. Medema2, Paul Nurse1, Mark Petronczki1,4, and Charles Swanton1,3
1The Francis Crick Institute, London, United Kingdom 2The Netherlands Cancer Institute, 
Amsterdam, the Netherlands 3CRUK UCL/Manchester Lung Cancer Centre of Excellence 
4Boehringer Ingelheim, Vienna, Austria
#
 These authors contributed equally to this work.
Abstract
Intercellular heterogeneity, exacerbated by chromosomal instability (CIN), fosters tumor 
heterogeneity and drug resistance. However, extreme CIN correlates with improved cancer 
outcome, suggesting that karyotypic diversity required to adapt to selection pressures might be 
balanced in tumors against the risk of excessive instability. Here, we used a functional genomics 
screen, genome editing, and pharmacologic approaches to identify CIN-survival factors in diploid 
cells. We find partial anaphase-promoting complex/cyclosome (APC/C) dysfunction lengthens 
mitosis, suppresses pharmacologically induced chromosome segregation errors, and reduces 
naturally occurring lagging chromosomes in cancer cell lines or following tetraploidization. 
APC/C impairment caused adaptation to MPS1 inhibitors, revealing a likely resistance mechanism 
to therapies targeting the spindle assembly checkpoint. Finally, CRISPR-mediated introduction of 
cancer somatic mutations in the APC/C subunit cancer driver gene CDC27 reduces chromosome 
segregation errors, whereas reversal of an APC/C subunit nonsense mutation increases CIN. Subtle 
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variations in mitotic duration, determined by APC/C activity, influence the extent of CIN, allowing 
cancer cells to dynamically optimize fitness during tumor evolution.
Significance—We report a mechanism whereby cancers balance the evolutionary advantages 
associated with CIN against the fitness costs caused by excessive genome instability, providing 
insight into the consequence of CDC27 APC/C subunit driver mutations in cancer. Lengthening of 
mitosis through APC/C modulation may be a common mechanism of resistance to cancer 
therapeutics that increase chromosome segregation errors.
Introduction
Chromosome missegregation leads to abrupt changes in gene expression and protein 
stoichiometry that result in a strong negative selection pressure when occurring in most 
diploid cell types, but which are tolerated in aneuploid cancer cells (reviewed in ref. 1). At 
least part of the selection against aneuploidy relies on p53, which limits cell propagation 
after chromosome missegregation and genome-doubling (2–4). Under selective pressure, 
however, chromosomal instability (CIN) enables cells to explore various karyotypic states, 
allowing the eventual emergence of subclones with improved fitness, a recurrent mode of 
adaptation observed in fungal pathogens, yeast, and mammalian cells, and a cause of 
treatment failure (5–17). Murine models largely support the notion that CIN favors tumor 
formation, but conversely excessive CIN appears to suppress tumorigenesis, analogous to 
mutational meltdown and error-prone catastrophe in bacterial and viral genetics (18–21). 
Although CIN has been generally associated with poor prognosis, patient stratification based 
on the degree of CIN has revealed that extremes of CIN are associated with improved 
prognosis, lending credence to the “just-right” threshold of genomic instability sufficient for 
tumor adaptation proposed by Cahill and colleagues (22–26). Excessive CIN appears 
deleterious for cell fitness, and, accordingly, enhancing chromosome missegregation has 
been proposed as an approach to target CIN cancer cells (18, 27, 28). Hence, selection could 
favor the attenuation of CIN in human cancer to prevent excessive genome instability while 
ensuring sufficient karyotypic instability to foster adaptation to a changing environment. 
Here, we explore cellular mechanisms contributing to the adaptation of excessive CIN in 
human cancer.
Results
Experimental Model for CIN Threshold and Tolerance
To investigate how cells respond and adapt to whole-chromosome missegregation, we sought 
a method to induce CIN in diploid cells that was amenable to high-throughput screening. 
Given the crucial role of the spindle assembly checkpoint (SAC) for chromosome 
segregation fidelity, we took advantage of reversine, an inhibitor of the SAC kinase MPS1 
encoded by the gene TTK (29, 30). We investigated whether reversine titration could tune 
the frequency of segregation errors in cells. The hTERT-immortalized diploid epithelial cell 
line RPE1 and near-diploid HCT116 colorectal cancer cells were chosen for their karyotypic 
stability and refractoriness to CIN, which is largely due to their functional p53 pathway (2). 
We measured segregation error rates by centromeric FISH from RPE1 daughter cell pairs 
born during acute reversine exposure in mitosis. Reversine increased the error rate per 
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chromosome pair per division in a dose-dependent manner, from 0.00027 in DMSO-treated 
cells (approximately 1 error per 165 divisions, assuming a diploid karyotype with equal error 
rates for all chromosomes) to 0.021 in 250 nmol/L (1 error per 2 divisions), 0.055 in 500 
nmol/L (1.3 chromosome errors per division on average), 0.183 in 750 nmol/L (4.2 
chromosomes per division), and 0.232 in 1 μmol/L reversine (5.3 chromosomes per division; 
Fig. 1A; Supplementary Table S1). Reversine treatment resulted in the p53-dependent 
expression of p21 (CDKN1A) and reduced proliferation in RPE1 and HCT116 cells, 
reflecting the activation of a cellular stress response to aneuploidy following a single 
passage through mitosis (Supplementary Fig. S1 A–S1F; ref. 2). TP53 RNAi increased the 
proliferation of RPE1 cells in reversine, reflecting greater tolerance to CIN and aneuploidy 
(Supplementary Fig. S1B; ref. 2). Phosphorylation of p53 at serine 15 was not detectable 
after reversine treatment, and the ATM inhibitor KU-55933 did not block p21 induction in 
reversine, suggesting that an ATM-mediated DNA-damage response was not the underlying 
cause for cell-cycle arrest (Supplementary Fig. S1G and S1H). We conclude that reversine 
titration allows control over the rate of chromosome segregation errors in otherwise diploid 
cells, thereby mimicking varying levels of CIN induction.
We next used reversine titration to examine the selective advantage of a genetic background 
permissive to CIN in response to increasing levels of CIN, by comparing HCT116 wild-type 
and TP53−/− isogenic cell lines (31). TP53 disruption provided a clear proliferative 
advantage in low concentrations of reversine (150–250 nmol/L) over a 72-hour period, but 
this difference was less pronounced when CIN levels were further increased (300–500 
nmol/L; Fig. 1B). In a long-term assay, TP53 disruption enabled colony formation in 200 
nmol/L reversine, whereas 500 nmol/L reversine severely impaired colony formation in both 
cell lines (Fig. 1C). These observations suggest that CIN tolerance caused by TP53 loss 
enables proliferation only when the segregation error rate is kept within a narrow window, 
beyond which excessive instability can no longer be tolerated (18, 27). We hypothesize that 
there might be selective pressures to prevent excessive CIN during cancer evolution in order 
to improve cell fitness.
A Synthetic Viability RNAi Screen for CIN Identifies APC/C Subunits
To identify genetic alterations that might promote survival following the induction of 
chromosome segregation errors, we performed a genome-wide siRNA screen in RPE1 cells 
exposed to 250 nmol/L reversine (Fig. 1D). Automated image acquisition and analysis was 
used to rank the effect of each siRNA pool on overall proliferation, based on cell number 
and the fraction of cells expressing the proliferation markers cyclin A2 and Ki-67. The 
screen identified seven subunits of the anaphase-promoting complex/cyclosome (APC/C) E3 
ligase complex (CDC16, CDC23, CDC27, ANAPC1, ANAPC4, ANAPC5, ANAPC10), 
along with one of its E2 ligases UBE2C (UBCH10) whose knockdown conferred a 
proliferative advantage in reversine (Fig. 1D; Supplementary Table S2 for a gene ontology 
enrichment analysis). This phenotype could be validated with multiple siRNA duplexes 
targeting each subunit in RPE1 cells and was reproduced in HCT116 cells (Supplementary 
Fig. S2A–S2F). Collectively, the multitude of siRNA duplexes tested and subunits targeted 
suggest that our results are a consequence of on-target reduction in APC/C activity.
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The SAC functions by inhibiting the APC/C during the early stage of mitosis until 
chromosome bi-orientation is achieved at metaphase, which in turn silences SAC signaling 
and triggers anaphase onset by allowing APC/C bound to its coactivator CDC20 to degrade 
securin and cyclin B (29). The duration from nuclear envelope breakdown to anaphase 
(NEBD–anaphase) therefore represents the time during which the SAC is active and 
monitors chromosome attachment to the mitotic spindle (32). Of note, complete 
pharmacologic inhibition of the APC/C or genetic ablation of the co-activator CDC20 
robustly arrests cells at metaphase (33, 34), indicating that the RNAi conditions used here 
result in partial APC/C loss of function. APC/C subunit RNAi rescued cell-cycle arrest 
following MAD2 RNAi or reversine-induced SAC impairment, and reduced the number of 
micronuclei, suggesting that fewer segregation errors were occurring, in contrast to TP53 
siRNA which did not reduce micronuclei formation (Fig. 1E; Supplementary Fig. S3A–
S3C). FISH analyses confirmed that CDC16 RNAi or transient inhibition of proteasomal 
degradation with MG132 efficiently reduced the rate of segregation errors in reversine-
treated cells (Fig. 1F; Supplementary Table S1; Supplementary Fig. S3D–S3F). These 
results are consistent with previous observations that imposing a long metaphase arrest (>80 
minutes) using 12 μmol/L of the APC/C inhibitor proTAME can rescue segregation errors in 
MAD2-depleted cells (35). However, our initial analysis revealed that RNAi against various 
APC/C subunits, such as ANAPC10 or CDC16 RNAi, increased mitotic duration by less 
than 15 minutes in 500 nmol/L reversine (Supplementary Fig. S3G). To further explore how 
small changes in NEBD-anaphase duration affect chromosome segregation fidelity, we 
performed time-lapse fluorescence microscopy on RPE1/H2B-mCherry cells treated with 
350 nmol/L reversine in combination with low doses of proTAME (1.5 μmol/L, 3 μmol/L, 4 
μmol/L), which inhibits the APC/C by competing with the coactivator CDC20 (Fig. 1G and 
H; ref. 36). Under these conditions, we observed a mitotic delay of 6 to 19 minutes (from 16 
minutes in reversine to 22, 31, and 35 minutes when combined with 1.5 μmol/L, 3 μmol/L, 
and 4 μmol/L proTAME, respectively), along with an increase in the number of cells that 
achieved bi-orientation (Fig. 1G). Longer NEBD-anaphase durations correlated with a 
progressive reduction in segregation errors from 90% to 34% (Fig. 1G). This indicates that 
partial APC/C dysfunction, resulting in mild delays in mitotic progression, can have 
profound effects in limiting the frequency of chromosome segregation errors.
CDC27 Haploinsufficiency Confers Resistance to CIN
The observation that impaired APC/C activity could reduce the rate of segregation errors 
prompted us to investigate the relationship between APC/C mutations and CIN in cancer. We 
surveyed 30 cancer types from The Cancer Genome Atlas (TCGA) totaling 7,781 individual 
tumors. Depending on the cancer type, 0.7% to 22.9% of tumors harbored a nonsynonymous 
mutation in an APC/C subunit (median, 6%; average, 8%; Supplementary Table S3). 
Although this was not above the expected mutation rate for a group of 15 genes using 
randomization tests, it has already been established that the APC/C subunit CDC27 (also 
known as ANAPC3) is one of 23 cancer driver genes in colorectal cancer (37, 38), and was 
also identified in testicular germ cell tumors (ref. 39; these studies consider nonsynonymous 
point mutations). CDC27 is the most frequently mutated APC/C subunit (Supplementary 
Table S4), and, strikingly, it displays a high incidence of truncating mutations (30.3%) 
distributed widely across the gene (Fig. 2A; Supplementary Table S4). It is unusual to 
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observe recurrent frameshift mutations such as the deletion creating L454Hfs*9, which may 
reflect an alignment error in the TCGA pipeline. Nevertheless, CDC27 would still bear a 
truncating mutation frequency of nearly 20% (34/179 = 19%) if those samples were 
excluded. CDC27 could be considered a candidate tumor suppressor according to the 20/20 
rule, because truncating mutations represent close to 20% of all reported mutations (40). 
Truncating mutations are also predicted to have a clear detrimental impact on APC/C 
complex structural integrity based on the atomic structure (see details below; ref. 41), and 
heterozygous mutations could lead to fewer active complexes in the cell.
In order to test if CDC27 truncating mutations confer a selective advantage during the onset 
of CIN, we used CRISPR/Cas9 to engineer three RPE1 populations carrying CDC27 
frameshift mutations by infecting cells with a lentiCRISPR vector at a low multiplicity of 
infection (MOI; Fig. 2A guide RNAs 1-2-3 and Fig. 2B). We reasoned that each polyclonal 
population would contain a mixture of mostly wild-type cells with some CDC27 
heterozygous cells (because CDC27 is an essential subunit; ref. 42). CRISPR-targeted 
populations were exposed to 250 nmol/L reversine continuously for over 4 weeks, which 
was lethal to RPE1/lentiCRISPRVector cells except for rare clones. In contrast, RPE1/
lentiCRISPRCDC27 populations rapidly adapted and could be continuously passaged in 
reversine (Fig. 2C and D; Supplementary Fig. S4A). This procedure resulted in a strong 
enrichment for clones with heterozygous CDC27 disruption after reversine treatment 
compared with untreated populations (CDC27-1: 100% vs. 8.7%; CDC27-2: 100% vs. 26%; 
CDC27-3: 93% vs. 4.3%; Supplementary Fig. S4B). Reversine washout after selection 
caused a delay of 9 to 10 minutes in anaphase onset, resulting in an apparent accumulation 
of mitotic cells, consistent with the selection of cells with impaired APC/C activity (Fig. 2D 
and E). CDC27 haploinsufficiency is therefore sufficient to confer a selective advantage 
under conditions that would otherwise lead to extreme CIN and lethality.
Deleterious CDC27 Mutations Are Selected in Cancer
To further explore if CDC27 mutations found in cancer disrupt APC/C activity, we took 
advantage of the sequence similarity between human and Schizosaccharomyces pombe 
(fission yeast) proteins, and the possibility to assay mutations in a haploid context. We tested 
a subset of mutations for which a homologous residue is found in S. pombe (NUC2 for 
CDC27), and assayed their ability to rescue lethality of NUC2 deletion in haploid spores 
(Supplementary Fig. S5A). Truncating NUC2 at position E600, which corresponds to one of 
the most C-terminal CDC27 nonsense mutations in human cancers (E736*), did not support 
growth (Fig. 2A and F). Similarly, substituting the homologous residue in NUC2 to mimic 
CDC27 G506E caused lethality, whereas the R629K mutation resulted in slow growth with 
delayed cyclin B degradation in mitosis (Fig. 2F; Supplementary Fig. S5B). CDC27 forms a 
homodimer within the APC/C complex and mediates the interaction with the Ile-Arg motif 
(IR tail) of a co-activator and the IR tail of APC10 in a symmetrical manner, which is 
required for substrate recognition by the APC/C (refs. 41, 43; Supplementary Fig. S5C). 
Examination of the human APC/C atomic structure (41, 43) revealed that the CDC27 G506E 
mutation would disrupt the IR tail binding site required for the interaction with the 
coactivators (CDH1 and CDC20) and with APC10. In addition, truncating CDC27 at E736 
would also reduce contact with the IR tail and WD40 domain of APC/C coactivators, with 
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the IR tail of APC10, and with the CDC16 subunit. E736* and any upstream CDC27 
truncating mutations often found in cancer would therefore severely impair APC/C activity 
and likely behave as null alleles, in line with the lethality of NUC2 E600* in S. pombe. To 
test this in human cells, we repeated the reversine selection assay described in Fig. 2B using 
three new CDC27 lentiCRISPR populations, including two that targeted the region around 
residue E736 and one designed to disrupt CDC27 near E468 (Fig. 2A, guides 4-5-6). We 
found that truncating human CDC27 near E736 was just as efficient in conferring resistance 
to prolonged reversine treatment as upstream truncating mutations (Supplementary Fig. 
S5D). This confirms that all CDC27 truncating mutations reported in TCGA are likely to be 
functionally relevant (except Q793*, which has not been tested). We also applied the same 
protocol to disrupt ANAPC1 and ANAPC4 near their respective most frequent truncation 
site reported in TCGA, also revealing rapid adaptation to reversine (Supplementary Fig. 
S5D). Deleterious mutations in CDC27 and other APC/C subunits can therefore be selected 
for in cancer and impair APC/C activity.
To examine the consequence of a CDC27 truncating mutation in unperturbed conditions, we 
engineered RPE1 cells in which one allele contained the single base deletion that creates the 
L454Hfs*9 truncation (Fig. 2A and G). Monoallelic disruption of CDC27 was sufficient to 
significantly delay anaphase onset by less than 3 minutes compared with wild-type clones or 
the parental population (P ≤ 0.0006), revealing that mitotic duration is sensitive to APC/C 
gene dosage even without selective pressure imposed by sustained MPS1 inhibition.
Impact of Cancer-Associated Missense Mutations on APC/C Structure
To gain further insight into the consequence of APC/C missense mutations, we analyzed the 
published APC/C structure (41) to assess the impact of a subset of mutations on the 
structural integrity of the complex (Supplementary Table S5). We restricted our analysis to 
APC/C mutations reported in nine cancer types (bladder, breast, colon, head and neck, 
glioblastoma multiforme, clear cell kidney carcinoma, lung adenocarcinoma, lung squamous 
cell carcinoma, and melanoma). A total of 132 missense mutations were examined in 
various subunits, 93 of which affected residues that could be mapped onto the APC/C 
structure (ref. 41; Supplementary Table S5). Fifteen mutations occurred in the catalytic and 
substrate recognition subunits, and may compromise E2 recruitment and substrate binding, 
respectively. In total, 40 mutations are predicted to disrupt the structural integrity of the 
APC/C (Supplementary Table S5). At least 60 of 132 mutations were also predicted to be 
deleterious based on MutationAssessor (44) or PolyPhen-2 (45). In summary, potentially 
deleterious missense mutations in several APC/C subunits are found in cancer.
APC/C Dysfunction Confers Resistance to MPS1 Inhibitors
The pharmacologic induction of CIN has been proposed as a therapeutic approach to target 
cancer cells (27), and several MPS1 inhibitors have been developed for this purpose, some 
of which are currently in drug development (clinicaltrials.gov identifiers NCT02366949, 
NCT02138812, and NCT02792465). Understanding the resistance mechanisms to such 
inhibitors and predicting how this might occur mechanistically is essential to improve drug 
design and potentially identify exploitable synthetic lethal pathways. In a previous study, 
recovery of HCT116 clones resistant to a lethal dose of the MPS1 inhibitor Compound-5 
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(Cpd-5) led to the identification of mutations in the MPS1 kinase domain that conferred 
resistance to various MPS1 inhibitors (46). However, six resistant clones did not carry a 
TTK mutation based on cDNA sequencing (46). Here, we performed targeted exon 
sequencing of these six clones for TTK, TP53, UBE2C, and all APC/C subunits and found 
two of the six clones carried a CDC16R136H heterozygous mutation, which is a highly 
conserved arginine residue. Interestingly, R136H clones displayed a longer mitotic duration 
while grown in Cpd-5 compared with untreated parental cells, and Cpd-5 washout prolonged 
NEBD-anaphase duration, suggestive of disrupted APC/C activity (Fig. 2H). In contrast, as 
expected, mitotic duration was unchanged with or without Cpd-5 in a clone bearing a 
mutation in the MPS1 kinase domain (I531M, Fig. 2H). Altered APC/C activity might 
therefore represent a resistance mechanism to MPS1 inhibitors distinct from the acquisition 
of somatic mutations in TTK itself.
APC/C Dysfunction Attenuates CIN after Genome Doubling
Next, we sought to examine whether APC/C dysfunction might also reduce CIN resulting 
from causes other than SAC defects. Genome doubling constitutes a precursor of CIN in 
several cancer types (47, 48), and experimental models have also shown that genome-
doubled (tetraploid) cells are tumorigenic and prone to CIN (3, 4, 47). We found that APC/C 
subunit nonsynonymous point mutations occurred significantly more frequently in genome-
doubled compared with non–genome-doubled tumors (58%; P = 0.005, Fisher exact test; 
Fig. 3A). Genome-doubling events, which can arise from cell division failure, inherently 
increase CIN due to the presence of extra centrosomes (3, 4). Extra centrosomes increase the 
formation of merotelic attachment errors, where a chromosome is attached to opposite poles 
(Supplementary Fig. S6A). If uncorrected, merotely may result in lagging chromosomes 
during chromosome separation and is considered to constitute a major cause of CIN in 
cancer (3, 4, 49–51). Efficient clustering of supernumerary centrosomes also prevents 
multipolar divisions, which result in extreme karyotypic changes and are most often lethal 
(Supplementary Fig. S6B; refs. 4, 52).
To directly assess the importance of APC/C activity in genome-doubled cells, we transiently 
blocked cytokinesis using Dihydrocytochalasin B (DCB) and examined the first division of 
binucleated cells with and without partial APC/C inhibition using 3 μmol/L proTAME (Fig. 
3B). Because cell-cycle progression beyond G1 is limited by p53 after tetraploidization (53), 
we performed these experiments in RPE1 cells where TP53 was disrupted using CRISPR/
Cas9 (Supplementary Fig. S7A and S7B). Time-lapse microscopy revealed 40% of 
binucleated cells underwent a bipolar division, and bipolarity was associated with a longer 
NEBD-anaphase duration, concordant with previous observations (refs. 52, 54, 55; Fig. 3C, 
DMSO). Partial APC/C inhibition using pro-TAME delayed anaphase onset and 
significantly increased the frequency of bipolar divisions in binucleated cells to 60% (P = 
0.01), suggesting that APC/C dysfunction provides more time for centrosome clustering to 
take place (Fig. 3C). Pro-TAME also caused a significant reduction in the frequency of 
lagging chromosomes among tetraploid cells undergoing bipolar divisions (27% to 8%, P < 
0.0001, Fig. 3D and E). These results suggest that APC/C dysfunction can stabilize genome-
doubled cells by preventing potentially catastrophic multipolar division, but also by reducing 
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the extent of CIN during bipolar divisions, likely by allowing more time for endogenous 
error-correction mechanisms to function.
APC/C Dysfunction Rescues Merotely
Merotelic attachment errors also occur in non–genome-doubled cells and compromise 
genome stability more than other types of attachment error because they do not activate the 
SAC and consequently do not delay mitotic progression to allow error correction. We 
induced merotely in RPE1/H2B-mCherry diploid cells by transiently arresting cells in 
mitosis with the Eg5 inhibitor S-Trityl-L-cysteine (STLC) and examined the importance of 
APC/C activity on merotelic attachment correction by live-cell imaging (Fig. 4A; 
Supplementary Fig. S6A; ref. 30). APC/C inhibition upon STLC release using 3 μmol/L 
proTAME delayed anaphase onset after STLC recovery by 23 minutes (110 to 133 minutes) 
and reduced the frequency of lagging chromosomes by 3.5-fold (39% to 11%, P < 0.0001; 
Fig. 4A and B). Within each condition (DMSO or 3 μmol/L proTAME), the time of 
anaphase onset was identical regardless of whether a segregation error occurred, confirming 
that these attachment errors have evaded SAC surveillance. Hence, APC/C dysfunction can 
reduce CIN caused by both SAC-impairment–dependent and –independent mechanisms. As 
expected, APC/C inhibition in mitosis did not reduce the frequency of structural aberrations 
(acentric and dicentric chromosomes) induced by premitotic replicative stress following 
aphidicolin treatment (Supplementary Fig. S8A and S8B). We conclude that although 
merotely cannot activate the SAC and in turn inhibit the APC/C, impaired APC/C activity 
creates a context favorable for endogenous error correction mechanisms to take place by 
delaying mitotic progression.
To further investigate how mild APC/C inhibition could facilitate error correction, we 
considered cyclin A2, a known APC/C substrate, whose degradation is not inhibited by SAC 
signaling in prometaphase, in contrast to cyclin B (32, 56). Sustained cyclin A2 levels were 
shown to create a permissive condition for error correction to take place during 
prometaphase by preventing premature stabilization of kinetochore–microtubule 
attachments, and its degradation below a permissive threshold might contribute to the step-
wise increases in stability observed from prometaphase to metaphase and anaphase (57). 
Given our previous observation that proTAME delays prometaphase progression (NEBD-
metaphase; Fig. 1G), we investigated whether a slight reduction in APC/C activity delayed 
cyclin A2 degradation in early mitosis. We used RPE1 cells in which an endogenous cyclin 
A2 allele has been tagged with the yellow-fluorescent protein Venus, allowing the 
quantification of its decay prior to anaphase (56). We observed that the decline of cyclin A2 
levels below 100% following NEBD was delayed from 6 to 15 minutes in the presence of 
1.5 μmol/L proTAME (the lowest dose used in our assays; Fig. 4C). Maintaining cyclin A2 
levels in early mitosis for a longer period of time might thus facilitate merotelic attachment 
correction and reduce segregation errors when APC/C is pharmacologically or mutationally 
impaired. Determination of spindle microtubule stability during prometaphase using a 
mCherry-photoactivatable-GFP-Tubulin construct in RPE1 cells revealed similar half-lives 
with or without proTAME (Supplementary Fig. S9 A and S9B). This supports a model 
whereby impaired APC/C simply prolongs the time during which cyclin A2 is maintained at 
a level permissive for efficient error correction to take place.
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CIN Attenuation through APC/C Dysfunction in Aneuploidy-Tolerant p53-Null Cells
Although TP53 is a major determinant of cellular proliferation following chromosome 
missegregation and its disruption is widely associated with CIN, aneuploidy tolerance 
mechanisms are probably unable to cope with the deleterious effects of excessive CIN that 
create extreme changes in gene dosage in cells suffering gain or loss of chromosomes (Fig. 
1B and C; Supplementary Figs. S1–S3). A larger proportion of APC/C-mutated than 
APC/C–wild-type tumors also carry a TP53 mutation in the cohort of nine cancer types 
analyzed (39% vs. 28%, P = 0.004; Fig. 5A, considering nonsynonymous point mutations 
exclusively), a correlation independent of genome-doubling status (P = 0.00263), but 
borderline significant when considering the higher mutational burden of TP53-mutated 
tumors (P = 0.079). We subjected RPE1/p53−/− populations to 250 nmol/L reversine for up 
to 8 weeks, and cells readily became resistant (Supplementary Fig. S10A). RPE1/p53−/− 
cells grown in reversine displayed a mitotic duration significantly longer than RPE1/p53−/− 
cells acutely treated with reversine (20 and 11 minutes, respectively, for NEBD-anaphase), 
but similar to RPE1/p53−/− cells that have never been exposed to reversine (18 minutes; Fig. 
5B). Drug washout significantly delayed NEBD-anaphase timing in reversine-adapted cells 
(50 minutes), and these cells maintained a longer NEBD-anaphase for several weeks after 
reversine removal, indicative of a transmissible and viable phenotype (Fig. 5B). Similar 
results were obtained in two RPE1-independent p53-null populations following drug 
adaptation and washout using 2 μmol/L AZ3146, an MPS1 inhibitor structurally unrelated to 
reversine (Supplementary Fig. S10B). RPE1/p53−/− reversine-adapted cells displayed greater 
cyclin B1 stability during a prolonged mitotic arrest in nocodazole compared with RPE1/
p53−/− cells that have never been exposed to reversine, confirming that APC/C activity is 
indeed reduced in the adapted population (ref. 58; Fig. 5C). Importantly, adaptation of 
RPE1/p53−/− cells in reversine was associated with a lower chromosome segregation error 
rate compared with RPE1/p53−/− cells acutely treated with reversine, with fewer lagging 
chromosomes when errors did occur (63% error with 2.8 lagging chromosomes on average 
vs. 91% with 5 lagging chromosomes, respectively; Fig. 5D). In addition, RPE1/p53−/− cells 
after adaptation (but grown without reversine for over 4 weeks) displayed fewer lagging 
chromosomes than treatment-naïve RPE1/p53−/− cells after STLC washout, indicative of 
fewer uncorrected merotelic attachments in adapted cells (Fig. 5E). Targeted exon 
sequencing on the RPE1/p53−/− adapted population did not reveal the clonal expansion of an 
APC/C subunit mutation, suggesting APC/C attenuation through parallel pathways that may 
involve transcriptional or epigenetic deregulation. Mitotic duration lengthening through 
attenuation of APC/C activity might therefore represent a common resistance mechanism to 
MPS1 inhibitors. We propose that even though p53-null cells display greater tolerance to 
segregation errors, which will undoubtedly contribute to CIN propagation, there is still a 
selective pressure to reduce CIN within a sustainable range, and impaired APC/C activity is 
one such mechanism to reach this equilibrium.
APC/C Inhibition or Frameshift Mutation Limits Chromosome Segregation Errors in CIN 
Cell Lines
To test whether partial APC/C inhibition could reduce the frequency of naturally occurring 
segregation errors in cancer cell lines, we chose three cell lines with a high frequency of 
anaphase lagging chromosomes (H2030 lung adenocarcinoma, U251 glioblastoma, and 
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SW480 colon carcinoma). We introduced H2B-mCherry to perform live-cell imaging using 
concentrations of proTAME that caused mild delays in anaphase onset (range of 4–13 
minutes) and measured the frequency of divisions with lagging chromosomes (Fig. 6A and 
B). Although each cell line showed a greater variation in basal NEBD-anaphase duration 
compared with untreated RPE1 or HCT116 cells, which likely reflects the phenotypic 
variability symptomatic of CIN, we observed a consistent reduction in lagging chromosomes 
with proTAME (Fig. 6B). These results suggest that impairing APC/C function can also 
reduce the rate of endogenous segregation errors in established CIN cancer cell lines.
To substantiate this finding, we generated H2030 cells bearing a frameshift mutation in one 
allele of CDC27 (Fig. 6C). H2030 cells were chosen because they efficiently formed 
colonies upon limiting dilution (unlike U251 or SW480). We first isolated a single H2030 
colony to avoid clonal variation due to CIN within the population and performed in-well 
transduction with a lentiCRISPR/CDC27 vector using a low viral titre. A second round of 
limiting dilution was then performed to identify rare clones in which gene editing took place 
in a single allele (Fig. 6C). We chose a guide RNA (gRNA) to disrupt CDC27 near the 
middle of the protein (Fig. 6D guide 7, having demonstrated previously that all CDC27 
truncating mutations disrupt APC/C activity). Disruption of a single CDC27 allele 
significantly delayed mitosis compared with three wild-type clones isolated in parallel, and 
was also associated with a significant reduction in lagging chromosomes (Fig. 6E and F). 
Monoallelic disruption of an APC/C subunit is therefore sufficient to reduce naturally 
occurring chromosome segregation errors.
Restoring APC/C Function Increases CIN
Finally, we took advantage of the CIN colorectal cancer cell line HT29, which carries an 
endogenous heterozygous nonsense mutation in the APC/C subunit CDC23 (also known as 
ANAPC8, amino acid position E245; Fig. 6G). We used a similar protocol as described 
above to limit clonal variation caused by CIN and transfected a single HT29 colony with a 
CRISPR/Cas9 construct together with a wild-type CDC23 single-stranded DNA (ssDNA) 
donor. Correction of the CDC23 E245* truncating mutation back to wild-type caused a 
modest decrease in mitotic duration, and a significant increase in the frequency of lagging 
chromosomes compared with three clones bearing a monoallelic E245* mutation (+/E245*; 
Fig. 6H and I).
Taken together, the mutational status of APC/C subunits can therefore directly affect 
chromosome segregation fidelity in cancer cells. These data suggest that several APC/C 
subunits, most notably CDC27, represent haploinsufficient tumor suppressors, owing to the 
delicate equilibrium required to maintain stoichiometry of the APC/C and its activity, with a 
role in preventing excess CIN thereby improving cell fitness.
Discussion
Mounting evidence from cancer genomics studies and experimental systems suggest that the 
degree of CIN determines its tumor-promoting or tumor-suppressive biological output, with 
excessive CIN associated with improved clinical outcome across several tumor types (18, 
19, 23, 24, 26, 27, 59, 60). This paradoxical relationship between CIN and cancer raises the 
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question of whether the optimal level of CIN in cancer cells is reached (and perhaps passed) 
in response to the stochastic acquisition of genetic alterations, or whether secondary 
alterations might be selected to prevent excessive CIN. The stochastic model implies that 
cancer cell fitness could decrease during tumor evolution, as cancer cells would likely 
accumulate more defects, increasing mitotic or premitotic chromosome missegregation 
events. The results presented here provide a potential mechanism through which cancer cells 
reduce their segregation error rate and therefore avoid the detrimental consequences of 
excessive CIN. Such a mechanism might have important consequences for tumor evolution 
because an intermediate level of CIN is more likely to be efficiently propagated by limiting 
cell-autonomous lethality, while still driving tumor cell diversification and heterogeneity, the 
substrate for selection and evolutionary fitness.
In support of this hypothesis, we show that cell populations can adapt to excessive CIN over 
a matter of weeks, by subtly lengthening mitotic duration. Mutations in APC/C subunits that 
would otherwise have very mild consequences on overall proliferation (in the range of 3 to 
15 minutes over an 18- to 24-hour cell cycle) might thus efficiently reduce segregation errors 
following cellular perturbations that have been recognized as some of the most potent CIN-
inducing defects, such as genome-doubling, merotelic attachment errors, and SAC 
dysfunction. APC/C mutations were also enriched in genome-doubled tumors, whereas our 
experimental evidence shows that APC/C inhibition increases the frequency of bipolar 
spindle formation and reduces CIN after genome doubling. This provides support for the 
selection of APC/C dysfunction to balance the beneficial consequences of rising cellular 
diversity against the fitness costs of excessive CIN. In addition, we provide functional 
evidence for the role of truncating mutations in the colorectal cancer driver CDC27 in 
rescuing cells from excessive CIN when segregation errors are experimentally elevated using 
MPS1 inhibitors. Importantly, monoallelic truncation of CDC27 in the CIN cell line H2030 
significantly reduced the frequency of lagging chromosomes. Conversely, restoring the 
heterozygous CDC23 E245* mutation naturally occurring in the CIN colorectal cell line 
HT29 back to wild-type caused an increase in lagging chromosomes, further indicating that 
APC/C mutations have a direct impact on chromosome segregation fidelity in cells with 
CIN. Our detailed analysis of cancer-derived APC/C mutations suggests that although the 
mutation frequency of the complex as a whole is not higher than would be expected by 
chance, many mutations are very likely to have a functional impact. This highlights key 
statistical issues with the derivation of driver gene status when considering large molecular 
complexes containing several different proteins, any one of which when mutated could 
potentially disrupt the function of the entire complex.
Limiting CIN might also be important to facilitate long-term survival in genetic backgrounds 
permissive for CIN, such as in TP53-disrupted cells, a relevant observation because 39% of 
tumors with an APC/C mutation also carry a TP53 mutation (2, 61). This likely reflects the 
limits that aneuploidy tolerance mechanisms can provide in response to overwhelming CIN 
that cells may experience during cancer evolution. We propose that genetic and epigenetic 
alterations affecting the expression or integrity of several APC/C subunits could affect the 
complex processivity, offering parallel avenues to select for impaired activity following the 
onset of CIN. Our findings also shed light on resistance mechanisms to therapeutics such as 
TTK inhibitors, which serve to increase chromosome missegregation. A number of cancer 
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drugs targeting mitotic processes, including paclitaxel, can lead to extreme CIN (62) and cell 
death, raising the possibility that APC/C mutations might also be a resistance mechanism to 
other anticancer drugs that function by precipitating chromosome segregation errors. 
Compensatory mechanisms may be important to mitigate several types of genomic 
instabilities during cancer development and restrict the generation of structural chromosomal 
aberrations. For example, telomere crisis early during cancer development followed by 
telomerase reactivation (hence stabilization) has been described for a number of cancer types 
(63–66). DNA-repair processes are upregulated in choroid plexus carcinoma, a type of brain 
tumor harboring extensive somatic DNA copy-number alterations, and focal amplification of 
syntenic genes with roles in DNA repair found to be important for tumor maintenance was 
proposed to help stabilize cancer cells following the acquisition of extensive rearrangements 
(67). Restoration of homologous recombination has also been described as a mechanism of 
resistance to PARP inhibitors in BRCA1/2-deficient tumors (67, 68). Numerous 
compensatory mechanisms might thus be selected during tumorigenesis and the acquisition 
of drug resistance in order to stabilize the various sources of genomic instability and 
optimize fitness.
The delicate nature of the evolutionary trade-off between the advantages of increased 
cellular diversity for subsequent generations, balanced against the fitness costs of excessive 
CIN, could offer therapeutic opportunities to exploit the CIN paradox in cancer medicine. 
Targeting mechanisms that limit CIN in tumors, forcing cells past a threshold of CIN 
tolerance, might provide a compelling strategy to limit tumor evolution and adaptation.
Methods
Cell Lines
All cell lines used in this study were obtained from the ATCC unless stated otherwise and 
reauthenticated by the London Research Institute’s Cell Services core facility (now Francis 
Crick Institute) by short tandem repeat DNA profiling (hTERT-RPE-1, June 2015; HCT116 
from ECACC, February 2015; HCT116 wild-type (+/+) and p53−/−, June 2010, a generous 
gift from Bert Vogelstein; H2030, October 2015; U251, January 2015; SW480, October 
2015; HT29, June 2016) and regularly tested to confirm absence of Mycoplasma. H2B-
mCherry was introduced by lentiviral delivery (Addgene plasmid 21217, a gift from Mark 
Mercola). RPE1/Cyclin A2-Venus heterozygous cells were a generous gift from Jonathon 
Pines (The Institute of Cancer Research, London, UK).
RNAi Screen
The primary screen was performed using the human siRNA Smart-pool siGenome library 
from Dharmacon, whereas the secondary screen was performed using the corresponding 
deconvoluted siRNA duplexes (where four siRNAs included in the pool were tested 
independently). Contact-inhibited RPE1 cells were reverse-transfected in triplicate 384-well 
plates using Lullaby transfection reagent [OZ Biosciences, 800 cells/well, 0.2 μL Lullaby/
well, 18.75 nmol/L siRNA, 250 nmol/L reversine (Sigma)] using a Biomek FX liquid 
handling robot (Beckman). Cells were cultured for 96 hours and fixed with 4% 
formaldehyde (ThermoFisher, no. 28908), except for the deconvolution experiment, where 
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cells were pulsed for 1 hour with 10 μmol/L EdU before fixation to label cells in S phase. 
Cells were subsequently permeabilized and blocked in PBS + 3% BSA + 0.2% Triton-X100 
for 30 minutes and processed for immunofluorescence (IF) and EdU detection 
(LifeTechnology) according to the manufacturer’s protocol. Images were acquired and 
analyzed using an ArrayScan VTi-automated microscope (Cellomics), except for total cell 
counts, which were acquired on an Acumen Explorer eX3 laser scanning microplate 
cytometer (TTPLabtech). For each parameter, a median Z-score was derived using plate 
normalization [(well value – plate median)/plate Median Absolute Deviation].
FISH
Unsynchronized RPE1 cells were treated with the indicated concentrations of reversine for 2 
hours. Mitotic cells were collected by mitotic shake-off and seeded on glass coverslips, 
while still in reversine, for 2 hours until daughter cells reattached. Cells were allowed to 
swell in 0.56% KCl for 5 minutes, fixed in ice-cold 3:1 methanol:acetic acid for 15 minutes, 
and dehydrated with successive 5-minute incubations in 70%, 85%, and 99.9% ethanol. 
Hybridization to centromeric probes for chromosomes 6, 7, 8, 10, 11, or 18 was performed 
following the manufacturer’s protocol (Cytocell). Daughter cells where the centromeric 
signal was within a micronucleus were excluded because it could belong to either cell. 
Measured rates are therefore likely an underestimate of the actual rate.
Immunofluorescence Microscopy
For detection of interphase nuclear proteins, cells were fixed in 4% formaldehyde 
(ThermoFisher, cat. 28908). For segregation errors, RPE1 cells were fixed for 40 minutes in 
ice-cold MeOH, and HCT116 cells for 15 minutes in 0.2% Triton X-100, 10 mmol/L PIPES, 
5 mmol/L EGTA, 1 mmol/L MgCl2, and 4% formaldehyde. Primary and secondary 
antibodies were incubated in 3% BSA and 0.02% Triton X-100. FISH and interphase images 
were acquired on a Zeiss Axio Imager M2 microscope using a Plan-Neofluar 340/1.3 
numerical aperture (NA) oil objective lens (Zeiss) or Plan Apochromat 363/1.4 NA oil 
objective lens (Zeiss) equipped with an ORCA-ER camera (Hamamatsu) and controlled by 
Volocity 6.0.1. software (Improvision). For segregation error analyses and fluorescence live-
cell microscopy, images were acquired using an Olympus DeltaVision RT microscope 
equipped with 40×, 63×, and 100× Olympus 3100 or 360 1.4 NA UPlanSApo oil immersion 
objectives (Applied Precision, LLC) and a Coolsnap HQ2 camera. For segregation error 
analyses, cells were stained with antitubulin, anticentromere, and antipericentrin antibodies, 
along with DAPI to stain DNA. Anaphase cells were identified based on the spindle 
morphology using the tubulin channel (hence without prior knowledge of whether an error 
occurred or not). Note that 0.2-μm stacks across the whole cell were acquired, and 
deconvolution of image stacks was performed with SoftWorx Explorer (Applied Precision, 
LLC). For fluorescence live-cell imaging of H2B-mCherry, stacks of 2 μm were acquired. 
Long-term imaging and bright-field NEBD-anaphase analysis were done using an Incucyte 
FLR device equipped with a 20x objective (Essen BioScience).
Photoactivation experiments were performed on RPE1 cells stably expressing GPAC-tubulin 
+/− 3 μmol/L proTAME. GPAC variant 1 (69) was cloned N-terminally of human alpha 1b 
tubulin into pLVX. Cells were monitored until a bipolar mitotic spindle formed in early 
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mitosis (using the mCherry channel). Two sequential photoactivations were done 5 minutes 
apart in each cell to compare spindle stability as cells progressed during prometaphase, 
using a focused 405-nm laser on a 1-μm/9-μm region on one side of the spindle. Images 
were then acquired every 5 seconds for 3 minutes to monitor GFP fluorescence dissipation. 
These conditions did not cause photobleaching nor prevent progression into anaphase. 
Fluorescence intensity profiles for each activation event were thresholded to remove 
background noise and normalized. A nonlinear regression analysis was applied to the 
resulting data, to fit an exponential curve using Prism 6 software (GraphPad software) to 
measure the rate of tubulin turnover.
Antibodies and Dyes
The following antibodies were used for IF or western blot (WB): cyclin A [AT10 1:500-IF, 
gift from Julian Gannon (Francis Crick Institute)], Ki-67 (Abcam ab15580, 1:5,000-IF), p21 
(MH9, 1:2,000-IF; AC8, 1:1,000-WB, gift from J. Gannon), p53 (OP43 Calbiochem, 
1:1,000-IF/WB), p53-pS15 (Cell Signaling Technology, 1:1,000), CDC27 (AF3.1, 2 μg/mL, 
gift from J. Gannon), alpha-tubulin (Sigma, clone B512, 1:10,000-IF), anti-centromere 
antibodies (HCT-0100, 1:2,000; Immunovision), MKLP1 (BD Biosciences 612682, 1:1,000-
IF), CDC16 (Santa Cruz K-16, 1:1,000-WB), and GAPDH (Abcam ab8245, 1:80,000-WB). 
Secondary antibodies conjugated to Alexa Fluor 488, 568, 594, or 647 (Invitrogen/
ThermoFisher) were used for IF detection. EdU was detected by incubating cells for 30 
minutes in 100 mmol/L Tris-HCl pH8.5, 4 mmol/L CuSO4, 500 nmol/L Alexa Fluor 
Azide-488 or -647 (Invitrogen), and 100 mmol/L ascorbic acid. DNA was stained with 1 
μg/mL 4′,6-diamidino-2-phenylindole (DAPI; Molecular Probes).
Sequencing
An IonTorrent panel (Thermo Fisher Scientific) was designed to amplify all coding exons of 
TTK, TP53, UBE2C, CDC20, and the 14 core APC/C subunits (ANAPC1, 4, 5, 7, 10, 11, 
12, 13, 15, 16, CDC16, CDC23, CDC26, CDC27). Next-generation sequencing was 
performed, and mutation calling was performed as described previously (70).
CRISPR/Cas9
The following gRNA sequences were cloned into the lentiCRISPR vector (gift from Feng 
Zhang, Addgene plasmid 49535), as described (71):
CTCTTAGTCCATTAACCCCA (CDC27-gRNA 1)
TTGACTTACCTTGGGGTTAA (CDC27-gRNA 2)
CTTCTTCGAGGCAGTGCGTT (CDC27-gRNA 3)
TGAGCCTTCTTCGTGAAATG (CDC27-gRNA 4)
AAGTAAACGAGGGATTCTTT (CDC27-gRNA 5)
TCCTATTAAGAAGTAAACGA (CDC27-gRNA 6)
AGATTAAAGGCCTGAATCTG (CDC27-gRNA 7)
TCGACGCTAGGATCTGACTG (TP53-1)
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CGTCGAGCCCCCTCTGAGTC (TP53-2)
AGCAAAGGATGCAGCACCAG (ANAPC1-gRNA 1)
ACTGCCTTCCAAGACCAGCA (ANAPC1-gRNA 2)
CTTGGTATCAGCAAGAGCAA (ANAPC4-gRNA).
For precise genome editing, CDC27 guide 7 or the CDC23 gRNA below was cloned into 
eSpCas9(1.1) (gift from Feng Zhang, Addgene #71814) which expresses a mutant Cas9 with 
improved specificity compared with wild-type Cas9 (72). Cells were cotransfected with the 
corresponding ssDNA donor vectors which also carried a silent mutation to facilitate 
identification and prevent Cas9 editing of the donor template.
GAGATTCTGATACTTTTGCA (CDC23-gRNA)
CDC23 wild-type ssDNA donor
GGATGAAAGAGTTTTTTCTGGCTCATATATACACAGAGTTGCAGTTGATAGA
GGAGGCTCTGCAAAAGTATCAGAATCTCATTGATGTGGGCTTCTCTAAGAG
CTCGTA
CDC27 L454Hfs*9 ssDNA donor
AATACAAAGATAATATTAAGCATTTAAAACAGACCTGCTGCTGCTTTTTGTG
ATTAAAGGCCTGAATTTGAGGTGTGATTGTGGATATTTTCCCTTCTGAAATG
ATGGAAGAGTCCAA.
Virus particles were produced in 293T cells by cotransfecting lentiCRISPR vectors with 
psPAX2 and pMD2.G (Addgene Plasmid #12260 and #12259, gifts from Didier). RPE1 
cells were infected at low MOI to favor single viral integrants, followed by puromycin (5 
μg/mL) selection for 7 days.
Compounds
proTAME was obtained from BostonBiochem (I-440). Reversine (cat. no. R3904), STLC 
(cat. no. 164739), DCB (cat. no. D1641), Z-Leu-Leu-Leu-al (MG132, cat. no. C2211), and 
doxorubicin hydrochloride (cat. no. D1515) were obtained from Sigma.
APC/C Mutation Analysis
For the correlation between APC/C mutations and genome doubling, we used data from 
2,694 TCGA tumors, across nine cancer types for which both copy-number data and 
mutational status were available (see ref. 73): bladder urothelial carcinoma (n = 130), breast 
invasive carcinoma (n = 903), colon adenocarcinoma (n = 190), glioblastoma multiforme (n 
= 250), head and neck squamous cell carcinoma (n = 289), kidney renal clear cell carcinoma 
(n = 303), lung adenocarcinoma (n = 257), lung squamous cell carcinoma (n = 131), skin 
cutaneous melanoma (n = 241).
Amino acid positions reported are based on the following UniProt IDs: CDC27 (P30260); 
ANAPC1 (Q9H1A4); ANAPC2 (Q9UJX6); CDC27 (P30260); ANAPC4 (Q9UJX5); 
ANAPC5 (Q9UJX4); ANAPC7 (Q9UJX3); ANAPC10 (Q9UM13); ANAPC11 (Q9NYG5); 
ANAPC13 (Q9BS18); ANAPC15 (P60006); ANAPC16 (Q96DE5); CDC16 (Q13042); 
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CDC20 (Q12834); CDC23 (Q9UJX2); CDC26 (Q8NHZ8). Ninety-three of the 132 APC/C 
subunit mutations affected residues that were resolved on the APC/C atomic structure (PDB: 
4UI9). Each one was analyzed individually, and the predicted impact on the APC/C structure 
or function is detailed in Supplementary Table S5.
Pombe Strain Handling and Time-Lapse Imaging
Cell culture conditions and growth media were as previously described by Moreno and 
colleagues (74). In brief, cells were cultured in YE4S, and crosses were performed on 
MEA4S. The heterozygous NUC2 deletion strain was derived from the Bioneer collection 
(75). We used an internally tagged cdc13-GFP allele (ref. 76; kind gift from S. Hauf) for our 
single-cell cyclin B degradation analysis. Timelapse imaging was performed at 25°C on a 
DeltaVision Elite system (GE Healthcare). During imaging, cells were cultured in YE4S 
using a Cellasics microfluidics system coupled to an Y04C plate (EMD Millipore). Image 
analysis was performed using custom Matlab scripts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification of APC/C subunits in a genome-wide siRNA screen for CIN survival.
A, Chromosome segregation error rates determined by FISH in postmitotic daughter cells. 
RPE1 cells were treated with reversine for 2 hours, then mitotic cells were collected by 
shake-off and allowed to reattach in the presence of reversine, before fixation. Graph 
represents the average rate measured for chromosomes 6, 7, 8, and 10 (bars, average ± 95% 
CI). B, HCT116 wild-type and p53−/− isogenic lines were imaged for 72 hours by live-cell 
imaging. Cell density for each drug concentration was normalized to DMSO for wild-type 
and p53−/− cell separately. Fold difference in cell density of HCT116 p53−/− relative to wild-
Sansregret et al. Page 21
Cancer Discov. Author manuscript; available in PMC 2017 August 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
type is displayed for each drug concentration. C, Clonogenic assay using isogenic HCT116 
cells grown for 10 days in the presence or absence or reversine, as indicated. D, Genome-
wide RNAi screen for synthetic viability with MPS1 inhibition. RPE1 cells were 
synchronized in G0–G1 by contact inhibition, trypsinized, and reverse-transfected at low 
density in triplicate to allow uniform passage through mitosis. Cells were exposed to 250 
nmol/L reversine for 96 hours and fixed. Automated image acquisition and analysis were 
performed for various parameters, and Z-scores were derived based on median plate 
normalization for each siRNA pool. E, DAPI staining of fixed cells 48 hours following the 
indicated siRNA treatments with 250 nmol/L reversine where indicated. F, Chromosome 
segregation error rates measured by FISH as in A. Cells were transfected with a nontargeting 
or a CDC16 siRNA pool, and 48 hours later, cells were synchronized with a single 
thymidine block. Reversine was added 10 hours after thymidine release, prior to mitotic 
entry. Mitotic cells were collected at 12 hours by shake-off, allowed to reattach on coverslips 
still in the presence of reversine, and fixed (bars, average ± 95% CI). G, Time-lapse 
fluorescence microscopy of RPE1 cells expressing H2B-mCherry imaged every 3 minutes, 1 
hour following the addition of 350 nmol/L reversine +/− proTAME (pT), as indicated. The 
duration from NEBD to metaphase and metaphase to anaphase is shown for cells in which 
all chromosomes congressed to form a metaphase plate. Each row corresponds to a single 
cell (n > 60 cells each; bars, mean ± 95% CI). H, Sample images of segregation errors 
scored in G. Maximum intensity projections are shown for timeframes immediately 
preceding and following anaphase onset. Shown are examples of a correct division (no 
error), an example of a lagging chromosome following proper congression at metaphase 
(middle), and an example where anaphase occurred before all chromosomes congressed to 
the metaphase plate (congression defect, hence NEBD–metaphase could not be determined). 
Scale bar, 10 μm.
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Figure 2. APC/C mutations in human cancer.
A, Lollipop plot representing the distribution, frequency, and type of mutations reported for 
CDC27 across 30 cancer types (see Supplementary Table S3). Green dots indicate missense 
mutations and red dots truncating mutations (nonsense, frameshift, and splice site). All 
lollipop plots were retrieved and adapted from cBioPortal (77, 78). The locations of the 
CRISPR/Cas9 guide RNA (gRNA) targeting sites used in the following experiments are 
indicated. B, Schematics describing the reversine adaptation assay. RPE1 populations were 
generated by infecting cells at low titre with lentiCRISPR vectors expressing either one of 
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three different gRNAs targeting CDC27 (to control for possible off-target cleavage). Cells 
were grown in 250 nmol/L reversine by passaging cells when the dish became confluent or 
every 2 weeks, whichever came first. Approximate doubling times were derived from 
counting cells at every passage. For vector cells, additional plates were maintained in 
parallel to isolate rare resistant colonies (Supplementary Fig. S4). C, Doubling times of the 
RPE1/lentiCRISPR populations maintained in reversine as determined at days 14 and 28. D, 
Stills from time-lapse movies of the RPE1/lentiCRISPR/CDC27-2 population after 4 weeks 
in 250 nmol/L reversine. Note the actively dividing cells in reversine. Upon 24 hours 
following reversine washout, many round mitotic cells are visible, but these cells are delayed 
only in mitosis rather than arrested, as shown below in E (scale bar, 100 μm). E, Mitotic 
duration from NEBD–anaphase in three independent RPE1/lentiCRISPR CDC27 
populations exposed to 250 nmol/L reversine for 4 weeks. Cells were imaged in parallel 
while still in 250 nmol/L reversine or 24 hours following reversine washout (bars, mean 
± 95% CI; ***, P < 0.0001). F, Tetrad dissection of S. pombe strains and the genotype of 
each haploid spore bearing an extra allele (in red, mutated where indicated; see 
Supplementary Fig. S5A for mating scheme). Both the truncating mutation homologous to 
E736* (S. pombe E600*) and the missense mutant G506E (S. pombe G370E) failed to 
rescue NUC2 deletion lethality, indicating that they are deleterious mutations. WT, wild-
type. G, Precise genome editing was performed in RPE1 cells to delete a single base pair at 
codon L454 (CTA) in one CDC27 allele, thereby creating a frameshift and stop codon 9 
amino acids downstream. Mitotic duration from NEBD–anaphase was determined for the 
heterozygous L454Hfs*9 clone in parallel with the parental population and three nonedited 
clones isolated in parallel, all of which were never exposed to reversine. H, NEBD–anaphase 
duration of HCT116 clones isolated based on their resistance to the MPS1 inhibitor Cpd-5. 
Mitotic timings were either determined while cells were still maintained in 30 nmol/L Cpd-5 
or following Cpd-5 washout (bars, mean ± 95% CI; *, P < 0.05; **, P < 0.01; ***, P < 
0.0001; ns, nonsignificant).
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Figure 3. APC/C dysfunction reduces CIN caused by merotely and lagging chromosomes in 
cancer cell lines.
A, Genome-doubling status of tumors bearing a mutation in one of the APC/C subunits. 
Derived from 2,694 tumors from 9 cancer types for which mutational and copy-number data 
were available to determine genome-doubling status (**, P = 0.0014, Fisher exact test). B 
and C, Genome doubling (tetraploidization) was induced in RPE1/p53−/− cells by a 12-hour 
treatment with 4 μmol/L DCB to block cytokinesis. DCB was washed off, and cells were 
allowed to recover for 2 hours, after which 3 μmol/L proTAME or DMSO was added to the 
media and cells were imaged every 3 minutes to capture the first mitosis following 
tetraploidization. Mitotic duration from NEBD–anaphase was measured exclusively for 
binucleated cells, and the fraction of bipolar or multipolar divisions was scored (scale, 50 
μm; bars, mean ± 95% CI; **, P = 0.01 for division outcome, Fisher exact test). D and E, 
Cells were grown on glass coverslips, treated with DCB using the same protocol as 
described in C, and fixed for immunostaining. Genome-doubled cells were identified on the 
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basis of having four centrosomes (identified using pericentrin staining), and the frequency of 
anaphase lagging chromosomes was scored (***, P < 0.0001, Fisher exact test).
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Figure 4. APC/C dysfunction results in CIN buffering and adaptation to extreme CIN.
A and B, RPE1/H2B-mCherry cells were arrested in mitosis using 40 nmol/L STLC, 
collected by shake-off, and released into media containing 3 μmol/L proTAME or DMSO (t 
= 0h). Stacks were acquired every 3 minutes to determine anaphase onset (A) and the 
presence of lagging chromosomes (B; error bars, mean ± 95% CI). Sample images from 
movies are shown, and the arrow indicates a lagging chromosome in a cell without 
proTAME. Representative images are shown (scale bar, 10 μm). C, Degradation kinetics of 
cyclin A2-Venus fluorescence quantified from unsynchronized single cells as they progress 
through mitosis. 1.5 μmol/L proTAME or DMSO was added 2 hours before imaging. Total 
cell fluorescence was quantified and normalized to the level at NEBD. Curves end at 
anaphase onset (n = 24 cells per condition; error bars indicate SD; ***, P < 0.0001 Student t 
test). Time to reach 50% maximum intensity was used for statistical analysis.
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Figure 5. Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant p53-null 
cells.
A, Fraction of TP53-mutated tumors among samples that are either wild-type for all APC/C 
subunits or in which at least one APC/C subunit is mutated. Derived from 2,694 tumors from 
9 cancer types (bladder, breast, colon, and head and neck cancers, glioblastoma multiforme, 
kidney renal clear cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, and 
melanoma; **, P = 0.005, Fisher exact test). See Methods for the number of samples per 
tumor types. B, NEBD–anaphase duration of RPE1/p53−/− cells after acute treatment with 
250 nmol/L reversine (added 2 hours before imaging). In parallel, RPE1/p53−/− grown for 8 
weeks in reversine (adapted) were imaged while still in 250 nmol/L reversine and 1 hour 
after reversine washout, as indicated. The last column represents RPE1/p53−/− grown for 4 
weeks in reversine, followed by 5 weeks without reversine (bars, average ± 95% CI; ***, P 
< 0.0001). C, Cyclin B degradation kinetics determined by western blot from cells that were 
maintained in mitosis for the indicated duration with 50 nmol/L nocodazole (a microtubule 
poison). RPE1/p53−/− cells were maintained in nocodazole ± 3 μmol/L proTAME, whereas 
reversine-adapted RPE1/p53−/− cells (growing over 4 weeks in the absence of reversine) 
were maintained in nocodazole only. ImageQuant was used to normalize cyclin B levels to 
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GAPDH, and % cyclin B is expressed relative to t = 0h for each cell line. D, The fraction of 
anaphase cells with lagging chromosomes was determined for RPE1/p53−/− cells acutely 
treated with 250 nmol/L reversine, and RPE1/p53−/− reversine-adapted cells while 
maintained in reversine or grown without reversine 24 hours before fixation (***, P < 
0.0001, Fisher exact test). E, H2B-mCherry was introduced in RPE1/p53−/− cells and 
RPE1/p53−/− reversine-adapted that had been cultured at least 5 weeks without reversine. 
Merotelic attachments were induced using the STLC arrest/washout protocol, and the 
frequency of segregation errors was determined by time-lapse fluorescence microscopy 
(from three experiments; ***, P < 0.0001, Fisher exact test).
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Figure 6. APC/C subunit mutational status affects CIN in cancer cells.
A and B, H2B-mCherry was introduced in H2030, U251, and SW480 cell lines and NEBD–
anaphase duration (A) as well as the frequency of anaphase segregation errors (B) with and 
without proTAME was determined by time-lapse fluorescence microscopy. Stacks were 
acquired every 3 minutes, and an example of segregation error is shown for each cell line 
(scale bar, 10 μm; in A, bars, mean ± 95% CI of a representative experiment; in B, P values 
from Fisher exact test). C, Experimental procedure used to generate CRISPR/Cas9 edited 
H2030 and HT29 cells used for plots D to I. In each case, a single clone was infected 
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(lentiCRISPR/CDC27 for H2030) or transfected (espCas9(1.1)/CDC23 + ssDNA donor) in a 
well of a 96-well plate before the colony reached confluency. Following transfection or 
transduction, the colony was dispersed by limiting dilution into 96-well plates. Clones were 
then screened for heterozygous disruption of CDC27 in H2030 cells or correction of the 
heterozygous E245 nonsense mutation in HT29 cells. Nonedited clones identified during 
screening were used as controls. Phenotypic analysis of all newly derived cell lines was 
performed following minimal clonal expansion to limit phenotypic diversity that may be 
acquired due to ongoing CIN. D, Lollipop plot of CDC27 showing only truncating mutations 
reported in TCGA and the location of the guide RNA used to disrupt CDC27 in H2030 cells. 
The clone isolated contained a heterozygous 35-bp deletion creating the truncation 
I442Sfs*15. E, NEBD–anaphase duration was determined for the H2030 clones using 
phase–contrast time-lapse microscopy (3 minutes/frame; bars, average ± 95% CI). F, The 
frequency of anaphase lagging chromosomes was determined on fixed cells by indirect IF 
microscopy (*, P < 0.05; Fisher exact test). G, Lollipop plot of CDC23 showing only 
truncating mutations reported in TCGA and the HT29 nonsense mutation from HT29 cells. 
H, NEBD–anaphase duration was determined for HT29 clones using phase–contrast 
timelapse microscopy (3 minutes/frame; bars, average ± 95% CI). I, The frequency of 
anaphase lagging chromosomes was determined on fixed cells by indirect IF microscopy (*, 
P < 0.05; Fisher exact test).
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